Seven months into the year, there were already four reported deals valued at over $1 billion in 2023, as many as in all of 2022.
Subscribe today for access to
Articles and Reports
Diagnostics companies that invested heavily in COVID-19 products are relying on M&A transactions to restructure and transition.
In the first half of this year, US companies have cut the second-highest total of jobs since 2009, according to a recent report.
The outlook of the global genetic testing market based on recent reports from five financial consulting firms.
After an eventful month in the Illumina-GRAIL saga, the story may soon be over.
After a significant lull, M&As in the lab diagnostics space heated up in May, with several key deals announced.
The biggest story in M&A dealmaking continues to be the deal that’s being undone—Illumina’s acquisition of GRAIL.
Carl Icahn has decided to take his beef with Illumina’s board of directors over the acquisition directly to company shareholders.
The deal closed Feb.22, but the FTC has expressed concerns about the acquisition and Amazon’s business practices in general.
Economic volatility and uncertainty is also making a significant impact on merger and acquisition activity in the diagnostics space.
The total market for PCR products will likely top $5 billion in 2023, according to a new report.
M&A activity in the clinical diagnostics space was significantly down in 2022 in terms of both deal volume and deal value.